Yiming Pharmaceutical: Transfer of 23% of the shares of the controlling shareholder agreement.

Yiming Pharmaceuticals announced a abnormal trading notice. The closing price of the company's stock on June 11th and 12th, 2025, increased by more than 20% for two consecutive trading days, indicating abnormal stock price fluctuations. In response to the abnormal stock fluctuations, the company conducted verification of its controlling shareholder and actual controller, confirming that the information previously disclosed by the company does not require correction or supplementation. The company's current operating situation is normal, and there have been no significant changes in the internal and external operating environment. The controlling shareholder and actual controller of the company did not buy or sell the company's stock during the period of abnormal stock trading, and the company did not violate the regulations on fair information disclosure. This equity change still needs to obtain a compliance confirmation from the Shenzhen Stock Exchange, and complete the share transfer registration procedures at the Shenzhen branch of the China Securities Depository and Clearing Corporation. The uncertainty remains whether this matter can be finally implemented and completed successfully.